We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why DaVita HealthCare (DVA) Fell More Than Broader Market
Read MoreHide Full Article
In the latest close session, DaVita HealthCare (DVA - Free Report) was down 1.33% at $152.37. The stock fell short of the S&P 500, which registered a loss of 0.4% for the day. On the other hand, the Dow registered a gain of 0.11%, and the technology-centric Nasdaq decreased by 0.73%.
Prior to today's trading, shares of the kidney dialysis provider had lost 1.2% was narrower than the Medical sector's loss of 10.07% and the S&P 500's loss of 7.34%.
Analysts and investors alike will be keeping a close eye on the performance of DaVita HealthCare in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $2.41, marking a 20.5% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $3.3 billion, up 2.36% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $14.16 per share and revenue of $14.11 billion. These totals would mark changes of +31.35% and +3.41%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for DaVita HealthCare. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. As of now, DaVita HealthCare holds a Zacks Rank of #2 (Buy).
In terms of valuation, DaVita HealthCare is presently being traded at a Forward P/E ratio of 10.91. Its industry sports an average Forward P/E of 17.48, so one might conclude that DaVita HealthCare is trading at a discount comparatively.
Investors should also note that DVA has a PEG ratio of 0.54 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Outpatient and Home Healthcare industry currently had an average PEG ratio of 1.76 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 99, finds itself in the top 41% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why DaVita HealthCare (DVA) Fell More Than Broader Market
In the latest close session, DaVita HealthCare (DVA - Free Report) was down 1.33% at $152.37. The stock fell short of the S&P 500, which registered a loss of 0.4% for the day. On the other hand, the Dow registered a gain of 0.11%, and the technology-centric Nasdaq decreased by 0.73%.
Prior to today's trading, shares of the kidney dialysis provider had lost 1.2% was narrower than the Medical sector's loss of 10.07% and the S&P 500's loss of 7.34%.
Analysts and investors alike will be keeping a close eye on the performance of DaVita HealthCare in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $2.41, marking a 20.5% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $3.3 billion, up 2.36% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $14.16 per share and revenue of $14.11 billion. These totals would mark changes of +31.35% and +3.41%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for DaVita HealthCare. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. As of now, DaVita HealthCare holds a Zacks Rank of #2 (Buy).
In terms of valuation, DaVita HealthCare is presently being traded at a Forward P/E ratio of 10.91. Its industry sports an average Forward P/E of 17.48, so one might conclude that DaVita HealthCare is trading at a discount comparatively.
Investors should also note that DVA has a PEG ratio of 0.54 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Outpatient and Home Healthcare industry currently had an average PEG ratio of 1.76 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 99, finds itself in the top 41% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.